智通财经APP获悉，派格生物医药-B(02565)高开近15%，截至发稿，涨14.94%，报72.7港元，成交额112.69万港元。
消息面上，11月14日，派格生物医药-B发布公告，中国国家药品监督管理局(国家药监局)已批准本公司核心产品PB-119的新药上市申请(新药上市申请)。
派达康®(PB-119)为本公司开发的新一代长效胰高血糖素样肽-1(GLP-1)受体激动剂，每周给药一次。该产品为国家科技重大专项认定为“重大新药创制”的国家原创1类新药。
根据第一期至第三期临床研究，PB-119在有效控制血糖与良好耐受性之间已达致最佳平衡，为中国2型糖尿病患者提供高效、安全的治疗选择。PB-119可显著改善β细胞功能，除血糖外，兼具全面管理患者的血压、血脂及体重，实现“四高共管，全面获益”。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.